Abstract

Brugmansia suaveolens Bercht. & J. Presl represents a promising source of new active molecules. Therefore, the aim of the study is to outline the profile of secondary metabolites and their therapeutic potential and in vitro safety properties. The identification of substances was carried out through the chromatographic profile, while the evaluation of therapeutic use was conducted through in vitro biological assays of antioxidant and antimicrobial activity and quantification of the total phenolic content. The safety of the extracts was evaluated using a cytotoxicity assay. The results found revealed the presence of different secondary metabolites, such as flavonoids and alkaloids. Biological assays showed promising antimicrobial activity in gram-negative strains. Regarding safety, greater cytotoxicity is observed in macrophage cells. The study demonstrated that the extracts are potent for therapeutic use, aiming at the development of a phytoproduct for topical use, providing an innovative, relevant and significant character for future research.

摘要

Brugmansia suaveolens Bercht。& J. Presl 代表了新活性分子的有前途的来源。因此，该研究的目的是概述次生代谢物的概况及其治疗潜力和体外安全特性。通过色谱图进行物质的鉴定，而通过抗氧化和抗菌活性的体外生物测定以及总酚含量的定量来进行治疗用途的评估。使用细胞毒性测定评估提取物的安全性。结果发现存在不同的次生代谢物，例如类黄酮和生物碱。生物学检测显示革兰氏阴性菌株具有良好的抗菌活性。关于安全性，在巨噬细胞中观察到更大的细胞毒性。该研究表明，这些提取物具有有效的治疗用途，旨在开发局部使用的植物产品，为未来的研究提供创新、相关和重要的特征。